Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Vox Sanguinis
|
October 28, 1998
Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS
L Biesert, H Suhartono
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|
July 1, 1995
Virus validation experiments on the production process of OCTAVI SDPlus
L Biesert, S Lemon, H Suhartono, et al.
Journal of Medical Virology
|
April 1, 1996
Viral safety of a new highly purified factor VIII (OCTATE)
L Biesert, S Lemon, A Goudeau, et al.
Archiv Der Pharmazie
|
March 1, 1995
[Pyrido(3,2-e)(1,4)diazepines--synthesis and testing of anti-HIV-1 activity]
K Görlitzer, C Wilpert, H Rübsamen-Waigmann, et al.
Behring Institute Mitteilungen
|
July 1, 1991
Biochemical and genetical analysis of AZT-resistant HIV-mutants
L Biesert, F Zimmermann, B Schröder, et al.
AIDS (London, England)
|
December 1, 1988
Inhibition of HIV and virus replication by polysulphated polyxylan: HOE/BAY 946, a new antiviral compound
L Biesert, H Suhartono, I Winkler, et al.
Medical Microbiology and Immunology
|
January 1, 1990
Anti-human immunodeficiency virus (HIV) drug HOE/BAY946 increases membrane hydrophobicity of human lymphocytes and specifically suppresses HIV-protein synthesis
L Biesert, M Adamski, G Zimmer, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society
|
September 1, 1995
Synthesis and bioactivity studies of 1-adamantanamine derivatives of peptides
S Horvat, L Varga-Defterdarović, J Horvat, et al.
Biologicals : Journal of the International Association of Biological Standardization
|
February 28, 2006
Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate)
M Stadler, G Gruber, C Kannicht, et al.
Infection
|
January 1, 1991
Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen
H Rübsamen-Waigmann, B Schröder, L Biesert, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Vox Sanguinis
|
October 28, 1998
Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS
L Biesert, H Suhartono
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|
July 1, 1995
Virus validation experiments on the production process of OCTAVI SDPlus
L Biesert, S Lemon, H Suhartono, et al.
Journal of Medical Virology
|
April 1, 1996
Viral safety of a new highly purified factor VIII (OCTATE)
L Biesert, S Lemon, A Goudeau, et al.
Archiv Der Pharmazie
|
March 1, 1995
[Pyrido(3,2-e)(1,4)diazepines--synthesis and testing of anti-HIV-1 activity]
K Görlitzer, C Wilpert, H Rübsamen-Waigmann, et al.
Behring Institute Mitteilungen
|
July 1, 1991
Biochemical and genetical analysis of AZT-resistant HIV-mutants
L Biesert, F Zimmermann, B Schröder, et al.
AIDS (London, England)
|
December 1, 1988
Inhibition of HIV and virus replication by polysulphated polyxylan: HOE/BAY 946, a new antiviral compound
L Biesert, H Suhartono, I Winkler, et al.
Medical Microbiology and Immunology
|
January 1, 1990
Anti-human immunodeficiency virus (HIV) drug HOE/BAY946 increases membrane hydrophobicity of human lymphocytes and specifically suppresses HIV-protein synthesis
L Biesert, M Adamski, G Zimmer, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society
|
September 1, 1995
Synthesis and bioactivity studies of 1-adamantanamine derivatives of peptides
S Horvat, L Varga-Defterdarović, J Horvat, et al.
Biologicals : Journal of the International Association of Biological Standardization
|
February 28, 2006
Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate)
M Stadler, G Gruber, C Kannicht, et al.
Infection
|
January 1, 1991
Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen
H Rübsamen-Waigmann, B Schröder, L Biesert, et al.
Page
of 1